NTV Asset Management LLC Sells 12,526 Shares of ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO)

NTV Asset Management LLC lessened its stake in shares of ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) by 27.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 32,661 shares of the company’s stock after selling 12,526 shares during the period. NTV Asset Management LLC owned about 0.94% of ALPS Medical Breakthroughs ETF worth $1,076,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Griffin Asset Management Inc. acquired a new position in ALPS Medical Breakthroughs ETF during the fourth quarter worth approximately $262,000. McGuire Investment Group LLC acquired a new position in ALPS Medical Breakthroughs ETF during the fourth quarter worth approximately $244,000. Kestra Advisory Services LLC increased its position in ALPS Medical Breakthroughs ETF by 16.2% during the third quarter. Kestra Advisory Services LLC now owns 14,186 shares of the company’s stock worth $386,000 after buying an additional 1,979 shares during the last quarter. Finally, Phoenix Wealth Advisors increased its position in ALPS Medical Breakthroughs ETF by 11.5% during the fourth quarter. Phoenix Wealth Advisors now owns 10,938 shares of the company’s stock worth $359,000 after buying an additional 1,130 shares during the last quarter.

ALPS Medical Breakthroughs ETF Price Performance

NYSEARCA SBIO traded up $0.59 during trading on Friday, reaching $34.45. 27,144 shares of the company’s stock were exchanged, compared to its average volume of 12,355. The business has a 50 day moving average price of $34.67 and a 200-day moving average price of $31.52. ALPS Medical Breakthroughs ETF has a fifty-two week low of $23.21 and a fifty-two week high of $38.80.

ALPS Medical Breakthroughs ETF Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.